Successful treatment of hepatitis B-associated leukocytoclastic vasculitis with lamivudine treatment in a child patient

ONAY O. S., BASKIN E., OZCAY F., Melek E., CANAN O., BILEZIKCI B.

RHEUMATOLOGY INTERNATIONAL, vol.27, no.9, pp.869-872, 2007 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 27 Issue: 9
  • Publication Date: 2007
  • Doi Number: 10.1007/s00296-006-0295-0
  • Journal Name: RHEUMATOLOGY INTERNATIONAL
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.869-872
  • Çukurova University Affiliated: No

Abstract

Chronic hepatitis B infection (HBI) has many extrahepatic manifestations such as vasculitis, glomerulonephritis, arthritis, dermatitis, pulmonary disease, and skin manifestations. The mechanism of these manifestations is thought to be immune mediated. Immune-suppressive treatment may enhance viral replication and worsen hepatic disease. Lamivudine is a nucleoside analogue used in chronic HBI treatment that works by suppressing replication of the hepatitis B virus (HBV). Recently, several reports have suggested that lamivudine treats vasculitis associated with HBV infection in adults. However, there are no data in the literature for children. Herein, we report a child with leukocytoclastic vasculitis due to chronic HBI who was successfully treated with lamivudine.